



IAP15 Rec'd PCT/PTO 24 JUL 2006

Atty. Dkt. No. 059314-0301

Applicant: Narinder K. CHAWLA, et al.

Title: CARBOHYDRATE-  
ASSOCIATED PROTEINS

Appl. No.: 10/534,578 ✓

International Filing Date: May 11, 2005  
371(c) Date:

Examiner: Unassigned

Art Unit: Unassigned

Confirmation Number: 3394

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first official action on the merits.

**RELEVANCE OF EACH DOCUMENT**

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date


July 24, 2006

By

Michele M. Simkin

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicant  
Registration No. 34,717



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: July 24, 2006

*(use as many sheets as necessary)*

**Complete if Known**

<b>Application Number</b>	10/534,578
<b>Filing Date</b>	05/11/2005
<b>First Named Inventor</b>	Narinder K. Chawla
<b>Group Art Unit</b>	Unknown
<b>Examiner Name</b>	Unknown
<b>Attorney Docket Number</b>	059314-0301

Sheet	1	of	18
-------	---	----	----

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document	Pages, Columns, Lines, Where	T <sup>6</sup>
-----------------------	--------------------------	-------------------------	---	--	---------------------------------	----------------

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)				Application Number	10/534,578
				Filing Date	05/11/2005
				First Named Inventor	Narinder K. Chawla
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	18	Attorney Docket Number	059314-0301

		Office e <sup>3</sup>	Number r <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	B1		WO95/25116		CALIFORNIA INST OF TECHN (US)	1995-09-21	
	B2		WO95/35505		UNIV LELAND STANFORD JUNIOR (US)	1995-12-28	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	C1	Adam, M.A., "Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions," (1988) <i>J. Virol.</i> 62:3802-3806		
	C2	Altschul, S.F. et al., "Basic local alignment search tool," (1990) <i>J. Mol. Biol.</i> 215:403-410		
	C3	Amado, M. et al., "Identification and characterization of large galactosyltransferase gene families: galactosyltransferases for all functions," (1999) <i>Biochim. Biophys. Acta</i> 1473:35-53		
	C4	Anderson, N.L., "A comparison of selected mRNA and protein abundances in human liver," (1997) <i>Electrophoresis</i> 18:533-537		
	C5	Antinozzi, P.A. et al., "Metabolic engineering with recombinant adenoviruses," (1999) <i>Annu. Rev. Nutr.</i> 19:511-544		
	C6	Apweiler, R. et al., "On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database," (1999) <i>Biochim. Biophys. Acta</i> 1473:4-8		
	C7	Armentano, D. et al., "Effect of internal viral sequences on the utility of retroviral vectors," (1987) <i>J. Virol.</i> 61:1647-1650		
	C8	Arndt, G.M. et al., "A rapid genetic screening system for identifying gene-specific suppression constructs for use in human cells," (2000) <i>Nucleic Acids Res.</i> 28:E15		
	C9	Asano, M. et al., "Growth retardation and early death of $\beta$ -1, 4-galactosyltransferase knockout mice with augmented proliferation and abnormal differentiation of epithelial cells," (1997) <i>EMBO J.</i> 16:1850-1857		
	C10	Ashkenazi, A. et al., "Apoptosis control by death and decoy receptors," (1999) <i>Curr. Opin. Cell Biol.</i> 11:255-260		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	3	of	18
		Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C11	Baltimore, D., "Intracellular immunization," (1988) <i>Nature</i> 335:395-396	
	C12	Bauer, G. et al., "Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized D34+cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes," (1997) <i>Blood</i> 89:2259-2267	
	C13	Bause, E. et al., "Molecular cloning and primary structure of Man9-mannosidase from human kidney," (1993) <i>Eur. J. Biochem.</i> 217:535-540	
	C14	Bender, M.A. et al., "Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region," (1987) <i>J. Virol.</i> 61:1639-1646	
	C15	Biederbick, A. et al., "A human intracellular apyrase-like protein, LALP70, localizes to lysosomal/autophagic vacuoles," (1999) <i>J. Cell Sci.</i> 112:2473-2484	
	C16	Biederbick A. et al., "First apyrase splice variants have different enzymatic properties," (2000) <i>J. Biol. Chem.</i> 275:19018-19024	
	C17	Bieberich, E. et al., "Man9-mannosidase from human kidney is expressed in COS cells as a Golgi-resident type II transmembrane N-glycoprotein," (1995) <i>Eur. J. Biochem.</i> 233:644-649	
	C18	Binari, R.C. et al., "Genetic evidence that heparin-like glycosaminoglycans are involved in wingless signaling," (1997) <i>Development</i> 124:2623-2632	
	C19	Bitter, G.A. et al., "Expression and secretion vectors for yeast," (1987) <i>Methods Enzymol.</i> 153:516-544	
	C20	Blaese, R.M. et al., "T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years," (1995) <i>Science</i> 270:475-480	
	C21	Blind, M. et al., "Cytoplasmic RNA modulators of an inside-out signal-transduction cascade," (1999) <i>Proc. Natl. Acad. Sci. USA</i> 96:3606-3610	
	C22	Boado, R.J. et al., "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS," (1998) <i>J. Pharm. Sci.</i> 87:1308-1315	
	C23	Bolton, A.E. et al., " (1973) <i>Biochem. J.</i> 133:529-539	
	C24	Bonay, P. et al., "Intra-Golgi Transport Inhibition by Megalomicin," (1996) <i>J. Biol. Chem.</i> 271:3719-3726	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	4	of	18
		Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C25	Bonyhadi, M.L., "RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication," (1997) <i>J. Virol.</i> 71:4707-4716	
	C26	Bordignon, C. et al., "Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients," (1995) <i>Science</i> 270:470-475	
	C27	Boulay, J.-L. et al., "Expression vectors and delivery systems," (1998) <i>Curr. Opin. Biotechnol.</i> 9:445-450	
	C28	Brody, E.N., "Aptamers as therapeutic and diagnosis agents," (2000) <i>J. Biotechnol.</i> 74:5-13	
	C29	Broglie, R. et al., "Light-regulated expression of a pea Ribulose-1,5-Bisphosphate Carboxylase small subunit gene in transformed plant cells," (1984) <i>Science</i> 224:838-843	
	C30	Brummelkamp, T.R. et al., "A system for stable expression of short interfering RNAs in mammalian cells," (2002) <i>Science</i> 296:550-553	
	C31	Buller, R.M. et al., "Decreased virulence of recombinant Vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype," (1985) <i>Nature</i> 317:813-815	
	C32	Burge, C. et al., "Finding the genes in genomic DNA," (1997) <i>J. Mol. Biol.</i> 268:78-94	
	C33	Burge, C. et al., "Prediction of complete gene structures in human genomic DNA," (1998) <i>Curr. Opin. Struct. Biol.</i> 8:346-354	
	C34	Burton, D.R., "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals," (1991) <i>Proc. Natl. Acad. Sci. USA</i> 88:10134-10137	
	C35	Capecchi, M.R., "Altering the genome by homologous recombination," (1989) <i>Science</i> 244:1288-1292	
	C36	Caruthers, M.H. et al., "New chemical methods for synthesis in polynucleotides," (1980) <i>Nucleic Acids Symp. Ser.</i> 7:215-223	
	C37	Cavazzana-Calvo, M. et al., "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease," (2000) <i>Science</i> 288:669-672	
	C38	Chang, C.-C. et al., "Evolution of a cytokine using DNA family shuffling," (1999) <i>Nat. Biotechnol.</i> 17:793-797	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	5	of	18
		Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C39	Chen, L. et al., "Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization," (1990) <i>Oncogene</i> 5:1391-1395	
	C40	Chicz, R.M. et al., "High-performance liquid chromatography: effective protein purification by various chromatographic modes," (1990) <i>Methods Enzymol.</i> 182:392-421	
	C41	Christians, F.C. et al., "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling," (1999) <i>Nat. Biotechnol.</i> 17:259-264	
	C42	Clarke, M.L. et al., "Comparative analysis of artificial antisense RNA regulation in fission yeast and human cells," (2000) <i>Biochem. Biophys. Res. Commun.</i> 268:8-13	
	C43	Colbere-Garapin, F. et al., "A new dominant hybrid selective marker for higher eukaryotic cells," (1981) <i>J. Mol. Biol.</i> 150:1-14	
	C44	Cole, S.P. et al., "Human monoclonal antibodies," (1984) <i>Mol. Cell Biol.</i> 62:109-120	
	C45	Coruzzi, G. et al., "Tissue-specific and light-regulated expression of a pea nuclear gene encoding the small subunit of rebusose-1,5-bisphosphate carboxylase," (1984) <i>EMBO J.</i> 3:1671-1680	
	C46	Cote, R.J. et al., "Generation of human monoclonal antibodies reactive with cellular antigene," (1983) <i>Proc. Natl. Acad. Sci. USA</i> 80:2026-2030	
	C47	Crameri, A. et al., "Improved green fluorescent protein by molecular evolution using DNA shuffling," (1996) <i>Nat. Biotechnol.</i> 14:315-319	
	C48	Crystal, R.G. et al., "A Phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung," (1995) <i>Hum. Gene Therapy</i> 6:643-666	
	C49	Crystal, R.G. et al., "Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis," (1995) <i>Hum. Gene Therapy</i> 6:667-703	
	C50	Crystal, R.G., "Transfer of genes to humans: Early lessons and obstacles to success," (1995). <i>Science</i> 270:404-410	
	C51	Csete, M.E. et al., "Efficient gene transfer to pancreatic islets mediated by adenoviral vectors," (1995) <i>Transplantation</i> 27:263-268	
	C52	Cunningham, B.C. et al., "Rational design of receptor-specific variants of human growth hormone," (1991) <i>Proc. Natl. Acad. Sci. USA</i> 88:3407-3411	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	6	of	18
		Attorney Docket Number	059314-0301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C53	Datta, A. et al., "Mutation of the sialyltransferase S-sialylmotif alters the kinetics of the donor and acceptor substrates," (1998) <i>J. Biol. Chem.</i> 273:9608-9618	
	C54	Datta, A. et al., "Sialylmotifs of sialyltransferases," (1997) <i>Indian J. Biochem. Biophys.</i> 34:157-165	
	C55	Datta, A. et al., "The sialyltransferase ``sialylmotif' participates in binding the donor substrate CMP-NeuAc," (1995) <i>J. Biol. Chem.</i> 270:1497-1500	
	C56	Dohi, T. et al., "Detection of N-acetylgalactosaminyltransferase mRNA which determines expression of Sda blood group carbohydrate structure in human gastrointestinal mucosa and cancer," (1996) <i>Int. J. Cancer</i> 67:626-631	
	C57	Drickamer, K. et al., "Biology of animal lectins," (1993) <i>Annu. Rev. Cell Biol.</i> 9:237-264	
	C58	Drickamer, K., "C-type lectin-like domains," (1999) <i>Curr. Opin. Struct. Biol.</i> 9:585-590	
	C59	Dryga, S.A. et al., "Identification of mutations in a sindbis virus variant able to establish persistent infection in BHK cells: The importance of a mutation in the nsP2 gene," (1997) <i>Virology</i> 228:74-83	
	C60	Dull, T. et al., "A third-generation lentivirus vector with a conditional packaging system," (1998) <i>J. Virol.</i> 72:8463-8471	
	C61	Duplaa, C. et al., "Quantitative analysis of polymerase chain reaction products using biotinylated dUTP incorporation," (1993) <i>Anal. Biochem.</i> 212:229-236	
	C62	Eddy, S.R., "Hidden markov models," (1996) <i>Curr. Opin. Struct. Biol.</i> 6:361-365	
	C63	Elbashir, S.M. et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," (2001) <i>Nature</i> 411:494-498	
	C64	Engelhard, E.K. et al., "The insect tracheal system: a conduit for the systemic spread of Autographa californica M nuclear polyhedrosis virus," (1994) <i>Proc. Natl. Acad. Sci. USA</i> 91:3224-3227	
	C65	Etienne-Decerf, J. et al., "Elevated anti- $\alpha$ -galactosyl antibody titres," (1987) <i>Acta Endocrinol.</i> 115:67-74	
	C66	Fields, S. et al., "A novel genetic system to detect protein-protein interactions," (1989) <i>Nature</i> 340:245-246	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	7	of	18
		Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C67	Fire, A. et al., "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ," (1998) <i>Nature</i> 391:806-811	
	C68	Freeze, H. et al., "Molecular basis of carbohydrate-deficient glycoprotein syndromes type I with normal phosphomannomutase activity," (1999) <i>Biochim. Biophys. Acta</i> 1455:167-78	
	C69	Fukushima, K., "Elevation of alpha2-->6 sialyltransferase and alpha1-->2 fucosyltransferase activities in human choriocarcinoma," (1998) <i>Cancer Res.</i> 58:4301-4306	
	C70	Furukawa, K. et al., "β-1,4-Galactosylation of N-glycans is a complex process," (1999) <i>Biochim. Biophys. Acta.</i> 1473:54-66	
	C71	Garoff, H. et al., "Recent advances in gene expression using alphavirus vectors," (1998) <i>Curr. Opin. Biotechnol.</i> 9:464-469	
	C72	Gatti, R.A. et al., "Localization of an ataxia-telangiectasia gene to chromosome," (1988) <i>Nature</i> 336:577-580	
	C73	Geremia, R. et al., "Glyco-Forum section," (1997) <i>Glycobiology</i> (letter) 7:v-vii	
	C74	Gilbert, M., "Cloning of the Lipooligosaccharide -2,3-Sialyltransferase from the Bacterial Pathogens <i>Neisseria meningitidis</i> and <i>Neisseria gonorrhoeae</i> ," (1996) <i>J. Biol. Chem.</i> 271:28271-28276	
	C75	Gish, K., "Breast Cancer: surveying half the human genome with transcription profiling for better diagnosis, prognosis, and therapy," (1999) <i>AWIS Magazine</i> 28:7-10	
	C76	Goins, W.F. et al., "Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity," (1999) <i>J. Virol.</i> 73:519-532	
	C77	Goldman, C.K. et al., "In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer," (1997) <i>Nat. Biotechnol.</i> 15:462-466	
	C78	Gossen, M. et al., "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters," (1992) <i>Proc. Natl. Acad. Sci. USA</i> 89:5547-5551	
	C79	Gossen, M. et al., "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters," (1995) <i>Science</i> 268:1766-1769	
	C80	Graham, F.L. et al., "A new technique for the assay of infectivity of human adenovirus 5 DNA," (1973) <i>Virology</i> 52:456-467	
	C81	Gura, T., "A silence that speaks volumes," (2000) <i>Nature</i> 404:804-808	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	8	of	18
		Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C82	Hadari, Y.R. et al., "Galectin-8; A new rat lectin, related to galectin-4," (1995) <i>J. Biol. Chem.</i> 270:3447-3453	
	C83	Haft, D.H. et al., "TIGRFAMs: a protein family resource for the functional identification of proteins," (2001) <i>Nucleic Acids Res.</i> 29:41-43	
	C84	Hansen, C. et al., "Glycosaminoglycans in autoimmunity," (1996) <i>Clin. Exp. Rheum.</i> 14:S59-S67	
	C85	Harrington, M.G., "Elution of protein from gels," (1990) <i>Methods Enzymol.</i> 182:488-495	
	C86	Harrington, J.J. et al., "Formation of de novo centromere and construction of first-generation human artificial microchromosomes," (1997) <i>Nat. Genet.</i> 15:345-355	
	C87	Hartman, S.C. et al., "Two dominant-acting selectable markers for gene transfer studies in mammalian cells," (1988) <i>Proc. Natl. Acad. Sci. USA</i> 85:8047-8051	
	C88	Hennet, T. et al., "Genomic cloning and expression of three murine UDP-galactose: -N-Acetylglucosamine 1,3-Galactosyl transferase genes," (1998) <i>J. Biol. Chem.</i> 273:58-65	
	C89	Higgins, D.G. et al., "CLUSTAL V: Improved software for multiple sequence alignment," (1992) <i>CABIOS</i> 8:189-191	
	C90	Higgins, D.G. et al., "Fast and sensitive multiple sequence alignments on a microcomputer," (1989) <i>CABIOS</i> 5:151-153	
	C91	Horenstein, B. et al., "Acid-catalized solvolysis of CMP-N-acetyl neuraminate: evidence for a sialylation with a finite lifetime," (1996) <i>J. Am. Chem. Soc.</i> 118:10371-10379	
	C92	Horn, T. et al., "Synthesis of oligonucleotides on cellulose. Part II: design and synthetic strategy to the synthesis of 22 oligodeoxynucleotides coding for Gastric Inhibitory Polypeptide (GIP)," (1980) <i>Nucleic Acids Symp. Ser.</i> 7:225-232	
	C93	Howard, A.D. et al., "Orphan G-protein-coupled receptors and natural ligand discovery," (2001) <i>Trends Pharmacol. Sci.</i> 22:132-140	
	C94	Huse, W.D. et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in Phage Lambda," (1989) <i>Science</i> 246:1275-1281	
	C95	Ivics, Z., "Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells," (1997) <i>Cell</i> 91:501-510	
	C96	Janne, J. et al., "Transgenic bioreactor," (1998) <i>Biotechnol. Annu. Rev.</i> 4:55-74	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)				Application Number	10/534,578
				Filing Date	05/11/2005
				First Named Inventor	Narinder K. Chawla
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	9	of	18	Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C97	Kannagi, R., "Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer," (1997) <i>Glycoconj. J.</i> 14:577-584	
	C98	Khazaie, K. et al., "EGF receptor in neoplasia and metastasis," (1993) <i>Cancer and Metastasis Rev.</i> 12:255-274	
	C99	Kimmel, A.R., "Identification and characterization of specific clones: Strategy for confirming the validity of presumptive clones," (1987) <i>Methods Enzymol.</i> 152:507-511	
	C100	Kohler, G. et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," (1975) <i>Nature</i> 256:495-497	
	C101	Kolbinger, F. et al., "Cloning of a human UDP-galactose:2-acetamido-2-deoxy-D-glucose 3 - galactosyltransferase catalyzing the formation of Type 1 chains," (1998) <i>J. Biol. Chem.</i> 273:433-440	
	C102	Kolm-Litty, V. et al., "High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells," (1998) <i>J. Clin. Invest.</i> 101:160-169	
	C103	Kozbor, D. et al., "Specific immunoglobulin production and enhanced tumorigenicity following ascites growth of human hybridomas," (1985) <i>J. Immunol. Methods</i> 81:31-42	
	C104	Kreppel, L. et al., "Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the Tetratricopeptide repeats," (1999) <i>J. Biol. Chem.</i> 274:32015-32022	
	C105	Kruszewska, J.S. et al., "Isolation of a <i>Trichoderma reesei</i> cDNA encoding GTP: α-D-mannose-1-phosphate guanylttransferase involved in early steps of protein glycosylation," (1998) <i>Curr. Genet.</i> 33:445-450	
	C106	Kwok, P.-Y. et al., "Single nucleotide polymorphism libraries: why and how are we building them?," (1999) <i>Mol. Med. Today</i> 5:538-543	
	C107	Lagerstrom, M. et al. (1991) <i>PCR Methods Applic.</i> 1:111-119	
	C108	Lander, E.S. et al., "Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms," (1986) <i>Proc. Natl. Acad. Sci. USA</i> 83:7353-7357	
	C109	Lasky, L.A., "Lectin cell adhesion molecules (LEC-CAMs): a new family of cell adhesion proteins involved with inflammation," (1991) <i>J. Cell. Biochem.</i> 45:139-146	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	10	of	18
		Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C110	Lasserre, C., "Structural organization and chromosomal localization of a human gene (HIP/PAP) encoding a C-type lectin overexpressed in primary liver cancer," (1994) <i>Eur. J. Biochem.</i> 224:29-38	
	C111	Laurent, T.C. et al., "Hyaluronan," (1992) <i>FASEB J.</i> 6:2397-2404	
	C112	Lee, S.W. et al., "Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment," (1992) <i>Proc. Natl. Acad. Sci. USA</i> 89:2504-2508	
	C113	Lepperdinger, G. et al., "HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity," (1998) <i>J. Biol. Chem.</i> 273:22466-22470	
	C114	Letunic, I. et al., "Recent improvements to the SMART domain-based sequence annotation resource," (2002) <i>Nucleic Acids Res.</i> 30:242-244	
	C115	Lin, Y. et al., "A hyaluronidase activity of the sperm plasma membrane protein PH-20 enables sperm to penetrate the cumulus cell layer surrounding the egg," (1994) <i>J. Cell Biol.</i> 125:1157-63	
	C116	Liu, X. et al., "Herpes simplex virus mediated gene transfer to primate ocular tissues," (1999) <i>Exp. Eye Res.</i> 169:385-395	
	C117	Logan, J. et al., "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection," (1984) <i>Proc. Natl. Acad. Sci. USA</i> 81:3655-3659	
	C118	Lois, C. et al., "Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors," (2002) <i>Science</i> 295:868-872	
	C119	Lokeshwar, V.B. et al., "Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression," (1996) <i>Cancer Res.</i> 56:651-657	
	C120	Lowman, H.B. et al., "Mutational analysis and protein engineering of receptor-binding determinants in human placental lactogen," (1991) <i>J. Biol. Chem.</i> 266:10982-10988	
	C121	Lowy, I. et al., "Isolation of transforming DNA: cloning the hamster apt gene," (1980) <i>Cell</i> 22:817-823	
	C122	Lueking, A. et al., "Protein microarrays for gene expression and antibody screening," (1999) <i>Anal. Biochem.</i> 270:103-111	
	C123	Maguire, T. et al., "Plasma sialyltransferase levels in psychiatric disorders as a possible indicator of HPA axis function," (1997) <i>Biological Psychiatry</i> 41:1131-1136	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	11	of	18
		Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C124	Manda et al., "Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display," (1999) <i>Genomics</i> 51:5-14	
	C125	Mantovani, A. et al., "Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines," (2001) <i>Trends Immunol.</i> 22:328-336	
	C126	Marshall, A. et al., "DNA Chips: an array of possibilities," (1998) <i>Nat. Biotechnol.</i> 16:27-31	
	C127	Marth, J.D., "Recent advances in gene mutagenesis by site-directed recombination," (1996) <i>Clin. Invest.</i> 97:1999-2002	
	C128	Masri, K.A. et al., "Identification of the full-length coding sequence for human galactosyltransferase ( $\beta$ -N-acetylglycosaminide: $\beta$ 1,4-galactosyltransferase)," (1988) <i>Biochem. Biophys. Res. Commun.</i> 157:657-663	
	C129	Matthews, D.J. et al., "Engineering an interfacial zinc site to increase hormone-receptor affinity," (1994) <i>Chem. Biol.</i> 1:25-30	
	C130	Matthijs, G., "Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome Type 1A," (1998) <i>Am. J. Hum. Genet.</i> 62:542-50	
	C131	Matthijs, G. et al., "Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type 1 syndrome (Jaeken syndrom)," (1997) <i>Nat. Genet.</i> 16:88-92	
	C132	McClain, D.A. et al., "Hexosamines and insulin resistance," (1996) <i>Diabetes</i> 45:1003-1009	
	C133	McGregor, D.P. et al., "Spontaneous assembly of bivalent single chain antibody fragments in <i>Escherichia Coli</i> ," (1994) <i>Mol. Immunol.</i> 31:219-226	
	C134	Melby, P.C. et al., "Quantitative measurement of human cytokine gene expression by polymerase chain reaction," (1993) <i>J. Immunol. Methods</i> 159:235-244	
	C135	Mendoza, L.G. et al., "High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA)," (1999) <i>Biotechniques</i> 27:778-788	
	C136	Mickelson, J.K. et al., "Differential expression and release of CD54 induced by cytokines," (1995) <i>Hepatology</i> 22:866-875	
	C137	Miller, A.D., "Progress toward human gene therapy," (1990) <i>Blood</i> 76:271-278	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	12	of	18
		Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C138	Morgan, R.A. et al., "Human gene therapy," (1993) <i>Annu. Rev. Biochem.</i> 62:191-217	
	C139	Morris, M.C. et al., "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," (1997) <i>Nucleic Acids Res.</i> 25:2730-2736	
	C140	Morrison, S.L. et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," (1984) <i>Proc. Natl. Acad. Sci. USA</i> 81:6851-6855	
	C141	Munster, A.K. et al., "Mammalian cytidine 5'-monophosphate <i>N</i> -acetylneuraminic acid synthetase: a nuclear protein with evolutionarily conserved structural motifs," (1998) <i>Proc. Natl. Acad. Sci. USA</i> 95:9140-9145	
	C142	Muyldermans, S., "Single domain camel antibodies: current status," (2001) <i>J. Biotechnol.</i> 74:277-302	
	C143	Nackaerts, K. et al., "Heparan sulfate proteoglycan expression in human lung-cancer cells," (1997) <i>Int. J. Cancer</i> 74:335-345	
	C144	Nagendra, A.R. et al., "CD18 integrin and CD54-dependent neutrophil adhesion to cytokine-stimulated human hepatocytes," (1997) <i>Am. J. Physiol.</i> 272:G408-G416	
	C145	Neuberger, M.S. et al., "Recombinant antibodies possessing novel effector functions," (1984) <i>Nature</i> 312:604-608	
	C146	Neumann, E. et al., "Gene transfer into mouse lymphoma cells by electroporation in high electric fields," (1982) <i>EMBO J.</i> 1:841-845	
	C147	Niehues, R. et al., "Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy," (1998) <i>J. Clin. Invest.</i> 101:1414-1420	
	C148	Nowotny, P. et al., "SNP analysis to dissect human traits," (2001) <i>Curr. Opin. Neurobiol.</i> 11:637-641	
	C149	Nuwaysir, E.F. et al., "Microarrays and toxicology: the advent of toxicogenomics," (1999) <i>Mol. Carcinog.</i> 24:153-159	
	C150	Okamoto H., "The Reg gene family and Reg proteins: with special attention to the regeneration of pancreatic $\beta$ -cells," (1999) <i>J. Hepatobiliary Pancreat. Surg.</i> 6:254-262	
	C151	Online Mendelian Inheritance In Man, 224100	
	C152	Orlandi, R. et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," (1989) <i>Proc. Natl. Acad. Sci. USA</i> 86:3833-3837	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)				Application Number	10/534,578
				Filing Date	05/11/2005
				First Named Inventor	Narinder K. Chawla
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	13	of	18	Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C153	Paddison, P.J. et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells," (2002) <i>Genes Dev.</i> 16:948-958	
	C154	Paietta, E. et al., "Hodgkin's cell lectin, a lymphocyte adhesion molecule and mitogen," (1989) <i>J. Immunol.</i> 143:2850-2857	
	C155	Parker, J.D. et al., "Targeted gene walking polymerase chain reaction," (1991) <i>Nucleic Acids Res.</i> 19:3055-3060	
	C156	Paulson, J. et al., "Glycosyltransferases. Structure, localization, and control of cell type- specific glycosylation," (1989) <i>J. Biol. Chem.</i> 264:17615-17618	
	C157	Perou, C.M. et al., "Molecular portraits of human breast tumours," (2000) <i>Nature</i> 406:747-752	
	C158	Petersen et al., "Gene therapy expression profiling of advanced lung cancer," (2000) <i>Int. J. Cancer</i> , 86:512-517	
	C159	Pitsillides, A.A. et al., "Uridine diphosphoglucose dehydrogenase activity in normal and rheumatoid synovium: the description of a specialized synovial lining cell," (1993) <i>Int. J. Exp. Pathol.</i> 74:27-34	
	C160	Poeschla, E. et al., "Development of HIV vectors for anti-HIV gene therapy," (1996) <i>Proc. Natl. Acad. Sci. USA</i> 93:11395-11399	
	C161	Price, C.M., "Fluorescence in situ hybridization," (1993) <i>Blood Rev.</i> 7:127-134	
	C162	Raghavan, S.S. et al., "Leukocyte $\beta$ -glucosidase in homozygotes and heterozygotes for Gaucher disease," (1980) <i>Am. J. Hum. Genet.</i> 32:158-173	
	C163	Ranga, U. et al., "Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene," (1997) <i>J. Virol.</i> 71:7020-7029	
	C164	Ranga, U. et al., "Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals," (1998) <i>Proc. Natl. Acad. Sci. USA</i> 95:1201-1206	
	C165	Rao, V.B., "Direct sequencing of polymerase chain reaction-amplified DNA," (1994) <i>Anal. Biochem.</i> 216:1-14	
	C166	Rhodes, C.A., "Transformation of maize by electroporation of embryos," (1995) <i>Methods Mol. Biol.</i> 55:121-131	
	C167	Riviere, I. et al., "Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells," (1995) <i>Proc. Natl. Acad. Sci. USA</i> 92:6733-6737	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  <i>(use as many sheets as necessary)</i>				Application Number	10/534,578
				Filing Date	05/11/2005
				First Named Inventor	Narinder K. Chawla
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	14	of	18	Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C168	Roberge, J.Y. et al., "A strategy for a convergent synthesis of N-linked glycopeptides on a solid support," (1995) Science 269:202-204	
	C169	Rossi, F.M.V. et al., "Recent advances in inducible gene expression systems," (1998) Curr. Opin. Biotechnol. 9:451-456	
	C170	Rossi, J.J., "Therapeutic antisense and ribozymes," (1995) Br. Med. Bull. 51:217-225	
	C171	Sager, R. et al., "Maspin: A tumor suppressing serpin," (1996) Curr. Top. Microbiol. Immunol. 213:51-64	
	C172	Sampson, P.M. et al., "Cytokine regulation of human lung fibroblast hyaluronan (hyaluronic acid) production. Evidence for cytokine-regulated hyaluronan (hyaluronic acid) degradation and human lung fibroblast-derived hyaluronidase. (1992) J. Clin. Invest. 90:1492-1503	
	C173	Sandig, V. et al., "Gene transfer into hepatocytes and human liver tissue by baculovirus vectors," (1996) Hum. Gene Ther. 7:1937-1945	
	C174	Sarkar, G., "Restriction-site PCR: a direct method of unknown sequence retrieval adjacent to a known locus by using universal primers," (1993) PCR Methods Applic. 2:318-322	
	C175	Sato, T. et al., "Differences in N-acetyllactosamine synthesis between $\beta$ -1,4-galactosyltransferases I and V," (1999) Glycoconj. J. 1999 16:73-76	
	C176	Scanlon, K.J. et al., "Oligonucleotide-mediated modulation of mammalian gene expression," (1995) FASEB J. 9:1288-1296	
	C177	Scharf, D. et al., "Heat stress promoters and transcription factors," (1994) Results Probl. Cell Differ. 20:125-162	
	C178	Schena, M. et al., "Quantitative monitoring of gene expression patterns with a complementary DNA microarray," (1995) Science 270:467-470	
	C179	Schultz, J. et al., "SMART, a simple modular architecture research tool: Identification of signaling domains," (1998) Proc. Natl. Acad. Sci. USA 95:5857-5864	
	C180	Schwarz, R.E. et al., "In vivo protein transduction: delivery of a biologically active protein into the mouse," (1996) Cancer Lett. 107:285-291	
	C181	Schwarze, S.R. et al., "In vivo protein transduction: delivery of a biologically active protein into the mouse," (1999) Science 285:1569-1572	
	C182	Schweden, J. et al., "Purification and characterization of a neutral processing mannosidase from calf liver acting on (Man) <sub>9</sub> (GlcNAc) <sub>2</sub> oligosaccharides (1986) Eur. J. Biochem. 157:563-570	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  <i>(use as many sheets as necessary)</i>		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	15	of	18
		Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C183	Schwientek, T. et al., "Golgi localization and <i>in vivo</i> activity of a mammalian glycosyltransferase (human $\beta$ 1,4-galactosyltransferase) in yeast," (1996) J. Biol. Chem. 271:3398-3405	
	C184	Scorer, C.A. et al., "Rapid selection using G418 of high copy number transformants of <i>Pichia Pastoris</i> for high-level foreign gene expression," (1994) Bio/Technology 12:181-184	
	C185	Shalon, D. et al., "A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization," (1996) Genome Res. 6:639-645	
	C186	Shaper, J., "Murine $\beta$ 1,4-galactosyltransferase," (1995) Adv. Exp. Med. Biol. 376:95-104	
	C187	Shaper, N.L. et al., "The chicken genome contains two functional nonallelic $\beta$ 1,4-galactosyl transferase genes," (1997) J. Biol. Chem. 272:31389-31399	
	C188	Shur, B., "Glycosyltransferases. Structure, localization, and control of cell type- specific glycosylation," (1993) Curr. Opin. Cell Biol. 5:854-863	
	C189	Shur, B. et al., "The receptor function of galactosyltransferase during cellular interactions," (1984) Mol. Cell. Biochem. 61:143-158	
	C190	Sjoberg, E. et al., "Molecular cloning of a developmentally regulated N-acetylgalactosamine 2,6-sialyltransferase specific for sialylated glycoconjugates," (1996) J. Biol. Chem. 271:7450-7459	
	C191	Skerra, A., "Anticalins: A new class of engineered ligand-binding proteins with antibody-like properties," (2001) J. Biotechnol. 74:257-275	
	C192	Slater, J.E. et al., "Environmental and occupational disorders," (1998) J. Allergy Clin. Immunol. 102:469-475	
	C193	Steiner, S. et al., "Expression profiling in toxicology—potentials and limitations," (2000) Toxicol. Lett. 112-113:467-471	
	C194	Su, L., "Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells <i>in vivo</i> and <i>in vitro</i> ," (1997) Blood 89:2283-2290	
	C195	Su, Z.-Z. et al., "Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family," (1996) Proc. Natl. Acad. Sci. USA 93:7252-7257	
	C196	Takamatsu, N., "Expression of bacterial chloramphenicol acetyltransferase gene in tobacco plants mediated by TRV-RNA," (1987) EMBO J. 6:307-311	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  <i>(use as many sheets as necessary)</i>		<b>Application Number</b>	10/534,578
		<b>Filing Date</b>	05/11/2005
		<b>First Named Inventor</b>	Narinder K. Chawla
		<b>Group Art Unit</b>	Unknown
		<b>Examiner Name</b>	Unknown
<b>Sheet</b>	16	<b>of</b>	18
		<b>Attorney Docket Number</b>	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C197	Takeda, S. et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," (1985) Nature 314:452-454	
	C198	Taylor, P.C. et al., "Immunotherapy for rheumatoid arthritis," (2001) Curr. Opin. Immunol. 13:611-616	
	C199	Taylor, S.I. et al., "Deconstructing type 2 diabetes," (2001) Trends Mol. Med. 7:507-512	
	C200	Thomson, J.A. et al., "Embryonic stem cell lines derived from human blastocysts," (1998) Science 282:1145-1147	
	C201	Trask, B.J., "Fluorescence in situ hybridization," (1991) Trends Genet. 7:149-154	
	C202	Triglia, T. et al., "A procedure for in vitro amplification of DNA segments that lie outside the boundaries of known sequences," (1988) Nucleic Acids Res. 16:8186	
	C203	Tsuji, S. et al., "Molecular cloning and functional analysis of sialyltransferases," (1996) J. Biochem. 120:1-13	
	C204	Uckert, W. et al., "Retrovirus-mediated gene transfer in cancer therapy," (1994) Pharmacol. Ther. 63:323-347	
	C205	Uejima, T. et al., "Complementary DNA cloning for galactosyltransferase associated with tumor and determination of antigenic epitopes recognized by specific monoclonal antibodies," (1992) Cancer Res. 52:6158-6163	
	C206	Ulrix, W. et al., "The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells," (1999) FEBS Lett 455:23-26	
	C207	Van Heeke, G. et al., "Expression of human synthetase in Escherichia coli," (1989) J. Biol. Chem. 264:5503-5509	
	C208	Verma, I.M. et al., "Gene therapy - promises, problems and prospects," (1997) Nature 389:239-242	
	C209	Wagner, K.U. et al., "Cre-mediated gene deletion in the mammary gland," (1997) Nucleic Acids Res. 25:4323-4330	
	C210	Wahl, G.M. et al., "Molecular hybridization of immobilized nucleic acids: theoretical concepts and practical considerations," (1987) Methods Enzymol. 152:399-407	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006  (use as many sheets as necessary)		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	17	of	18
		Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C211	Wakarchuk, W. et al., "Functional relationships of the genetic locus encoding the glycosyltransferase enzymes involved in expression of the Lacto-N-neotetraose terminal lipopolysaccharide structure in <i>Neisseria meningitidis</i> ," (1996) J. Biol. Chem. 271:19166-19173	
	C212	Wang et al., "Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis," (2000) Oncogene 19:1519-1528	
	C213	Weiss, G.A. et al., "Anticalins versus antibodies: made-to-order binding proteins for small molecules," (2000) Chem. Biol. 7:R177-R184	
	C214	Wigler, M. et al., "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells," (1977) Cell 11:223-232	
	C215	Wigler, M. et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene," (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570	
	C216	Winter, G. et al., "Man-made antibodies," (1991) Nature 349:293-299	
	C217	Winter, J. et al., "The expression of heat shock protein and cognate genes during plant development," (1991) Results Probl. Cell Differ. 17:85-105	
	C218	Wise, A. et al., "Target validation of G-protein coupled receptors," (2002) Drug Discovery Today 7:235-246	
	C219	Wistuba, I.I. et al., "Comparison of features of human breast cancer cell lines and their corresponding tumors," (1998) Clin. Cancer Res. 4:2931-2938	
	C220	Wolosker, H. et al., "Molecularly cloned mammalian glucosamine-6-phosphate deaminase localizes to transporting epithelium and lacks oscillin activity," (1998) FASEB J. 12:91-99	
	C221	Xu, H. et al., "Viral transduction of trkA into cultured nodose and spinal motor neurons conveys NGF responsiveness," (1994) Dev. Biol. 163:152-161	
	C222	Yadav, S.P. et al., "Identification of a region of UDP-galactose:N-Acetylglucosamine $\beta$ 4-galactosyltransferase involved in UDP-galactose binding by differential labeling," (1990) J. Biol. Chem. 265:14163-14169	
	C223	Yadav, S.P. et al., "Structure and function in galactosyltransferase," (1991) J. Biol. Chem. 266:698-703	
	C224	Yamamoto, H., " $\alpha$ 2,6-sialyltransferase gene transfection into a human glioma cell line (U373 MG) results in decreased invasivity," (1997) J. Neurochem. 68:2566-2576	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 24, 2006 <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/534,578
		Filing Date	05/11/2005
		First Named Inventor	Narinder K. Chawla
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet	18	of	18
		Attorney Docket Number	059314-0301

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C225	Yamamoto, H. et al., "β1,6-N-acetylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasity," (2000) Cancer Res. 2000 60:134-142	
	C226	Yu, M. et al., "A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus Type 1," (1993) Proc. Natl. Acad. Sci. USA 90:6340-6344	
	C227	Yuan, Y. et al., "Secreted fringe-like signaling molecules may be glycosyltransferases," (1997) Cell 88:9-11	
	C228	Zabner, J. et al. (1993) Cell 75:207-216	
	C229	Zhou, Z. et al., "Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors," (1998) Int. J. Cancer 78:95-99	
	C230	Zufferey, R. et al., "Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery," (1998) J. Virol. 72:9873-9880	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.